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IMMUNOHISTOCHEMICAL EVALUATION OF MUCIN EXPRESSION 
IN PRECANCEROUS TISSUE OF STOMACH
S. Vernygorodskyi
Department of Pathological Anatomy, Forensic Medicine and Law, Pirogov National Medical University, 
Vinnytsa, Ukraine
Aim: To assess the profile of mucins (MUC1, MUC2, MUC5AC) in gastric mucosa through immunohistochemical method. 
Methods: To identify metaplastic areas in gastric mucosa there was used chromoendoscopy with 0.5% solution of methylene blue, 
the expression of the mucins profile was determined using immunohistochemistry with MUC1, MUC5AC, MUC2 and MUC6 an-
tibodies (clone Ma695, clone CLH2, Ccp58 and CLH5, “Novocastra” Great Britain). Results: In case of the complete intestinal 
metaplasia (IM) there was maximum MUC2 expression in goblet cells. MUC5AC, MUC1 and MUC6 expression were absent 
in columnar epitheliocytes with brush border. In case of incomplete IM along with positive MUC2 marking of goblet cells, in 25% 
of such patients with chronic atrophic gastritis with incomplete IM MUC5AC expression has been observed; but in columnar 
epitheliocytes MUC5AC expression was observed in 100% of patients, and MUC2 expression was detected in 15% of patients 
only. Weak expression of MUC2 and MUC5AC in the areas adjacent to gastric adenocarcinoma was registered. Conclusion: 
MUC5AC expression in columnar epithelial cells and goblet exocrinocytes marks the formation of gastrointestinal phenotype — 
incomplete IM, along with the simultaneous production of MUC2 by goblet cells. Decrease of MUC 5AC expression in columnar 
epithelial cells and goblet exocrinocytes was found in areas of severe dysplasia and IM that may serve as an additional criterion 
of early malignization of gastric mucosa cells.
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Modern understanding of gastrointestinal barrier 
is associated with the ability of surface and glandular 
epithelial cells to synthesize mucin [1, 2]. At the same 
time epithelial mucins are a large group of secreted and 
embedded in plasmolemma glycoproteins produced 
by epithelial cells. In epithelial tissues 13 types of mucin 
are distinguished, forming two classes of compounds: 
transmembrane and secretory mucins. MUC1 is one 
of the transmembrane mucins of the digestive tract cells. 
It is distributed on the cell surface and acts as a signaling 
molecule. MUC3 and MUC4 are membrane-bound mu-
cins that play important roles in the protection of the epi-
thelial cells and have been implicated in epithelial renewal 
and differentiation. As for the gel-forming mucins of the 
digestive tract, they include: MUC2, MUC5AC, MUC4B, 
MUC6. They are actively expressed on epithelial cells 
and represent a variable number of peptides rich in ser-
ine, threonine and proline, coupled with a large number 
of oligosaccharide chains. According to the information 
available [3], the expression of membrane glycoproteins 
increases nearly tenfold in transformed cells, and car-
bohydrate chains are becoming shorter. Mechanisms 
that are responsible for orientation of protein molecules 
in the bilayer of cytomembrans, stabilization of the spatial 
structure of proteins, transmembrane and intracellular 
transport of substances (including transfer of hydrolytic 
enzymes from the Golgi complex to lysosomes), and 
molecular mechanisms of intercellular recognition are 
associated with the specific structure of the carbohydrate 
determinants of glycoproteins. It is known that these 
mechanisms play an important role in the maturation 
and differentiation of cells, histogenesis and organ 
morphogenesis, contact inhibition, cell proliferation that 
may be considered as the manifestations of malignant 
growth [4–7].
Today it is proven that chronic atrophic gastritis 
(CAG) is one of the main elements of gastric tumori-
genesis. According to the recommendations of the 
International Atrophy Group (2002) two main types 
of atrophy are distinguished: metaplastic and non-
metaplasic [8]. Non-metaplasic atrophy is charac-
terized by loss of glands, accompanied by fibrosis 
or fibromuscular proliferation in lamina propria 
of gastric mucosa, as for metaplastic atrophy — there 
is a replacement of gastric glands by metaplastic ones 
(including enteric), which can happen in the setting 
of other signs of atrophy. Disturbance of the synthesis 
and secrete releasing by glandular cells, its chemical 
composition change under the influence of exogenous 
and endogenous factors in CAG with intestinal meta-
plasia (IM) have not been studied well enough.
MATERIALS AND METHODS
Patients and methods. During 6 years there were 
examined 98 patients who were sent to endoscopy 
departments of Vinnytsya hospitals to clarify the clinical 
diagnosis. There were 52 male (53%) and 46 female 
patients (47%). Among these 98 patients we selected 
68 with chronic atrophic gastritis (CAG) with IM that were 
taken as a main group for further investigation because 
IM was closely associated with this disease. In this group 
42 patients were diagnosed as H. pylori-infected and 
26 patients as H. pylori-noninfected. The comparison 
group included 30 people with CAG without IM (16 pa-
teints H. pylori-infected and 14 — -noninfected). The 
average age of patients examined in dynamics was 
53 ± 1.1, average duration of disease at the time of IM di-
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agnosis — 2.6 ± 0.6 years. As the first-line therapy for 
eradication of H. pylori, all patients were treated by 10-
day triple therapy with omeprazole at a dose of 20 mg 
(twice daily), amoxicillin at a dose of 1 gm/day, and 
either metronidazole at a dose of 500 mg (twice daily).
Moreover, surgical specimens of gastric adenocar-
cinoma as well as adjacent mucosa were investigated 
(54 patients were enrolled into study: 28 adenocar-
cinoma, 12 signet-ring cell carcinoma and 14 undif-
ferentiated tumor, a distribution of patients according 
to TNM staging is given in table 1).
Table 1. Distribution of patients with gastric cancer according to TNM 
staging
Stage Number of patientsn %
ІA (T1N0M0)
ІB (T2N0M0)
4
21
7.4
38.9
ІІ (T3N0M0) 12 22.2
ІІІA (T3N1M0)
ІІІB (T3N2M0)
(T4N0M0)
4
4
2
7.4
7.4
3.7
IV (T4N1M0)
(T4N2M0)
(T3N2M1)
(T4N2M1)
2
3
1
1
3.7
5.5
1.9
1.9
Total 54 100
Multiple biopsies were performed during en-
doscopy and chromoendoscopy with 0.5% solution 
of methylene blue (two biopsies from the body and 
antrum and one — from an area of the angle of the 
stomach) taking into account the requirements of the 
modified Sydney system of chronic gastritis diagnosis 
and stained areas of gastric mucosa with the follow-
ing histological study of biopsies. Biopsy material was 
processed by conventional histologiocal methods. 
To define metaplastic changes of gastric mucosa the 
following methods were used: staining with hema-
toxylin and eosin and van Gisone, combined high iron 
diamine and alcian blue technique, orsein combined 
with alcian blue, Gomory aldehyde fuchsin, alcian blue 
with pH 1.0 and 2.5 together with the PAS reaction. 
H. pylori persistence has been conducted with a rapid 
urease test and with a Pappenheim stain as well as with 
Romanovsky — Giemsa and toluidine blue staining.
Immunohistochemistry. Immunohistochemi-
cal studies were performed on paraffin sections us-
ing streptavidin-biotin method (“DAKO”, Denmark, 
LSAB2 Systems, HRP. Expression of the mucins profile 
was determined using antibodies MUC1, MUC5AC, 
MUC2 and MUC6 (clone Ma695, clone CLH2, Ccp58 and 
CLH5, “Novocastra”, Great Britain). In preparations 
at 400-fold magnification we determined the rate of in-
testinal differentiation (nuclear label CDX2) in 5 randomly 
selected fields of view (≥ 500 cells) as a percentage share 
of positively stained nuclei of epithelial cells of gastric 
mucosa in three compartments (I — surface and foveolar 
epithelium; II — neck region, III — base of the glands, 
middle and lower third of the glands to the basal sec-
tions). To evaluate the expression of mucins (MUC5AC, 
MUC2, MUC6) in gastric mucosa in similar areas there 
was used semi-quantitative color intensity rating scale : 
0 (none) — no positive reaction in the cells, 1 (weak) — 
up to 30% of the cells reacted positively, 2 (moderate) — 
31–60%, 3 (strong) — 60% or more stained cells [9].
All sections were examined by three independent 
investigators. The mucins expression was evaluated 
by cytoplasmic staining. The results were expressed 
semiquantitatively for each histological group as the 
number of sections positively labeled, the predomi-
nant cell type labeled, and the average score of the 
positively labeled cells. Positive Control Sections: 
control tissues taken from colon and stomach, with 
previously identified MUC gene expression patterns 
were included with each batch of sections for immuno-
histochemistry. Negative Control Sections: the primary 
antibody was omitted as a negative control to test the 
specificity of the antibodies utilized for each section.
All patients were thoroughly informed about the 
study that was approved by the local ethics committee.
Statistical analysis. Results of immunohisto-
chemical alterations were compared to the clinico-
pathologic features using chi-square test with two 
tailed p-value, p < 0.05 was considered as significant.
RESULTS
It was shown that a certain cell phenotype corre-
sponds to some certain type of mucin. So, MUC5AC 
was found in the epithelium pits, MUC1 — in mucous 
neck cells, MUC6 — in the pyloric exocrinocytes, 
MUC2 — in goblet cells. The fact that MUC5AC is se-
lectively synthesized by epithelial cells of pits and 
necks of the gland cells of normal gastric mucosa 
allowed us to draw a conclusion that the epithelial 
cells of the necks of the glands may be classified 
as those producing mucus. Due to the low specificity 
of MUC1 binding of cytoplasmic mucus, we observed 
its weak expression in the cytoplasm of mucous neck 
cells only in 2 patients with CAG, and due to lack of pos-
itive binding in IM case we excluded it from further 
analysis. MUC5AC marking was highly informative in all 
the investigated cases. Thus, the expression of MUC 
5AC has not been defined in columnar epitheliocytes 
areas of complete IM despite strong and moderate 
expression in areas with incomplete IM (Fig. 1 a, b).
In H. pylori-infected group associated HAG the 
MUC5AC labeling was moderate and weak. After eradi-
cation of H. pylori infection the expression of several 
of them was amplified. MUC5AC expression prevailed 
in columnar epithelial cells in 21% of patients with in-
complete IM in the cytoplasm and membranes of gob-
let cells. In patients with a long history of CAG (over 
3 years) and over 6 years in the group subjected to dy-
namic monitoring, in 34% of patients loss of MUC5AC 
was observed in areas of incomplete IM and mild and 
severe dysplasia (Fig. 2).
Decrease of the number of mucin-positive cells was 
visible in areas of incomplete IM adjacent to tumor bor-
der and in cancer cells. However, in 37% of patients the 
MUC5AC expression remained in the IM areas adjacent 
to tumor and in neoplastic cells, which may predomi-
nantly indicate a gastric type of adenocarcinoma (Fig. 3).
116 Experimental Oncology 35, 114–117, 2013 (June)
ba
Fig. 1. a) Chronic atrophic gastritis with complete and in-
complete intestinal metaplasia (InCIM). Strong expression 
of MUC5AC in areas of incomplete IM (arrow) and lack of mucin 
expression in the areas of the complete IM (arrowhead). Immu-
nohistochemical staining, x100. b) Chronic atrophic gastritis with 
complete IM (CIM). Lack of MUC5 expression in epitheliocytes 
with complete IM (arrow) and moderate expression in superficial 
epitheliocytes (arrowhead) of the adjacent to metaplasia area. 
Immunohistochemical staining, x200.
ba
Fig. 2. Loss of MUC5AC expression in the foveolar epithelium (a) 
and surface epithelial cells (b) of incomplete IM areas and dysplasia 
in patients with chronic atrophic gastritis with incomplete intestinal 
metaplasia (arrow). Immunohistochemical staining, a) x400, b) x200
Fig. 3. Moderate MUC5AC expression in poorly differentiated 
gastric adenocarcinoma. Immunohistochemical staining, x400.
It should be noted that the loss of mucin-producing 
properties was observed mainly in patients with poorly 
differentiated adenocarcinoma, but in 44% of patients 
with cancer signet-ring cells carcinoma retained MU-
C5AC labeling. MUC2 expression was moderate in the 
cytoplasm and sometimes heavy in the membranes 
of goblet cells and remained during the observation 
in cases of complete and incomplete IM (Fig. 4). Goblet 
cells in the initial phases of secretion were wedge-
shaped with the apex, directed to the basal parts, with 
the foundation towards the lumen of the stomach.
Fig. 4. Moderate expression of MUC2 in goblet cells of stomach 
glands. Chronic antral atrophic gastritis with areas of complete 
and incomplete IM. Immunohistochemical staining, x200
In areas adjacent to adenocarcinoma the weak ex-
pression of MUC2 was registered. During the observa-
tion we found no positive labeling of MUC2 in the group 
of patients with gastric signet-ring cell adenocarci-
noma. MUC6 expression was observed mainly in the 
pyloric exocrinocytes of deep parts of lamina propria, 
it was weak in the areas of incomplete IM and it was 
lacking in complete IM. Thus the more profound was 
IM spread, the weaker was MUC6 expression, indicat-
ing a progressive displacement of pyloric glands with 
neogenic intestinal epithelium and severe IM (stage III 
of chronic atrophic metaplastic gastritis). While study-
ing biopsies from the fundus we have noted the positive 
labeling of exocrinocytes of the oxyntic glands (Fig. 5), 
that confirms their restructuring and the development 
of pyloric metaplasia (pylorization).
Fig. 5. Moderate expression of MUC6 in the pyloric exocrino-
cytes and focal expression in the oxyntic glands. Chronic atro-
phic fundic gastritis with incomplete IM. Immunohistochemical 
staining, x100
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So the findings of immunohistochemical analysis 
of mucins profile indicate some mucin specificity in dif-
ferent IM types (Table 2, 3).
Table 2. Chronic atrophic gastritis with complete intestinal metaplasia
Mucins SpecificitySFE MNC OE PC PE GS СCBB
MUC1 - + - - - - -
MUC2 +/- - - - - +++ -
MUC5AC - - ++ - - - -
MUC6 - - - - +++ - -
Notes: SFE — superficial and foveolar epithelium; MNC — mucous neck cells; 
OE — oxyntic exocrinocytes; PC — parietal cells; PE — pyloric exocrinocytes; 
GS — goblet cells; CCBB — columnar epithelial cells with brush border; MUC — 
mucin; — no expression; +/— weak or absent; + weak expression; ++ mod-
erate; +++ strong expression.
Table 3. Chronic atrophic gastritis with incomplete intestinal metaplasia
Mucins SpecificitySFE MNC OE PC PE GS СCBB
MUC1 + + - - - +++ -
MUC2 - - - - - +++ +/-
MUC5AC +++ ++ ++ - - +/- +++
MUC6 - + + - +++ - -
Notes: SFE — superficial and foveolar epithelium; MNC — mucous neck cells; 
OE — oxyntic exocrinocytes; PC — parietal cells; PE — pyloric exocrinocytes; 
GS — goblet cells; CCBB — columnar epithelial cells with brush border; MUC — 
mucin; — no expression; +/— weak or absent; + weak expression; ++ mod-
erate; +++ strong expression.
As it can be seen from table 3, when the IM was 
complete, the MUC2 maximum expression was visible 
in goblet cells, thus MUC5AC, MUC1 and MUC6 mark-
ing were absent in columnar epitheliocytes with brush 
border. When the IM was incomplete and MUC2 mark-
ing of goblet cells was positive, in 25% of patients with 
CAG with incomplete IM, the gastric mucin (MUC5AC) 
was observed as well as for columnar epitheliocytes, 
it was characteristic that the gastric mucin (MUC5AC) 
has been found in 100% of patients, and as for MUC2, 
it was observed in 15% of patients.
DISCUSSION
IM has been recognized as either a complete 
or an incomplete type IM, or as a small- (Type I and 
Type II) or large- (Type III) intestinal-type IM [10, 11]. 
Though these classifications have been generally 
accepted, they overemphasize the characteristics 
common to cells in the small intestine, while neglecting 
the existing gastric phenotype. But the results of our 
investigations coincide with other authors [12, 13] that 
suggested dividing intestinal metaplasia (IM) into two 
categories, i.e., a mixed gastric and intestinal (GI) type, 
and a solely intestinal (I) type, based on the residual 
gastric phenotype cells.
Thus separation of gastrointestinal phenotype 
of IM unlike previous classification [10, 11], which offered 
only intestinal types (mainly intestinal and colonic), will 
let us consider gastric and intestinal phenotype. It will 
let us deepen our knowledge about the histogenesis 
of gastric cancer and it confirms the heterogeneity of IM.
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